FOXA1 and acute myeloid leukemia: NR2F1-AS1 also exerts oncogenic effects by sponging miR-483-3p in acute myeloid leukemia (AML), enhancing IGF1 expression and fostering azacitidine resistance [60]; in osteosarcoma, NR2F1-AS1 targets miR-483-3p to upregulate FOXA1, driving malignant progression [61].